about
Analysis and Control of in Vivo Kinetics of Exosomes for the Development of Exosome-based DDSInduction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice.Efficient amplification of self-gelling polypod-like structured DNA by rolling circle amplification and enzymatic digestion.Depressive symptoms as a side effect of Interferon-α therapy induced by induction of indoleamine 2,3-dioxygenase 1.Controlling the kinetics of interferon transgene expression for improved gene therapy.DNA nanotechnology-based development of delivery systems for bioactive compounds.Fibronectin inhibits cytokine production induced by CpG DNA in macrophages without direct binding to DNA.Effect of exosome isolation methods on physicochemical properties of exosomes and clearance of exosomes from the blood circulation.Self-assembling DNA hydrogel-based delivery of immunoinhibitory nucleic acids to immune cells.Nasal delivery of Japanese cedar pollen Cryj1 by using self-gelling immunostimulatory DNA for effective induction of immune responses in mice.Enhancement of anticancer effect of interferon-γ gene transfer against interferon-γ-resistant tumor by depletion of tumor-associated macrophages.Efficient delivery of immunostimulatory DNA to mouse and human immune cells through the construction of polypod-like structured DNA.Transplantation of insulin-secreting multicellular spheroids for the treatment of type 1 diabetes in mice.Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice.Pharmacokinetics of Exosomes-An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of Exosome-Based Therapeutics.Role of Phosphatidylserine-Derived Negative Surface Charges in the Recognition and Uptake of Intravenously Injected B16BL6-Derived Exosomes by Macrophages.Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA.Quantitative analysis of tissue distribution of the B16BL6-derived exosomes using a streptavidin-lactadherin fusion protein and iodine-125-labeled biotin derivative after intravenous injection in mice.Inhibition of surgical trauma-enhanced peritoneal dissemination of tumor cells by human catalase derivatives in mice.Saturation of transgene protein synthesis from mRNA in cells producing a large number of transgene mRNA.Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice.Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression.Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells.Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors.Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1alpha expression in tumor cells and hepatocytes.Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus.Design of PCR-amplified DNA fragments for in vivo gene delivery: size-dependency on stability and transgene expression.Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA.Moment analysis for kinetics of gene silencing by RNA interference.Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases.Contribution of Epigenetic Modifications to the Decline in Transgene Expression from Plasmid DNA in Mouse Liver.Accelerated growth of B16BL6 tumor in mice through efficient uptake of their own exosomes by B16BL6 cells.Optimal Arrangement of Four Short DNA Strands for Delivery of Immunostimulatory Nucleic Acids to Immune Cells.Prevention of adverse events of interferon γ gene therapy by gene delivery of interferon γ-heparin-binding domain fusion protein in mice.Long-term elimination of hepatitis C virus from human hepatocyte chimeric mice after interferon-γ gene transfer.Reconstruction of Toll-like receptor 9-mediated responses in HEK-Blue hTLR9 cells by transfection of human macrophage scavenger receptor 1 gene.Cell type-specific and common characteristics of exosomes derived from mouse cell lines: Yield, physicochemical properties, and pharmacokinetics.Increased Insulin Secretion from Insulin-Secreting Cells by Construction of Mixed Multicellular Spheroids.Corrigendum: Efficient amplification of self-gelling polypod-like structured DNA by rolling circle amplification and enzymatic digestion.Gene delivery of albumin binding peptide-interferon-gamma fusion protein with improved pharmacokinetic properties and sustained biological activity.
P50
Q28066503-52505F8D-DD69-4BA7-85B6-1EF6A5F5CBBAQ33730763-85073825-2DE6-4F9B-9376-F8DDC7E637B8Q35805160-FB4987DB-D902-4148-8235-2F9CC0B2BDBAQ37111098-23EFCE7E-7C07-4F3A-9E81-983D81B8867BQ38044941-C57D199D-246E-4BA4-B158-C83A7D79AB0CQ38201564-82F2BA1C-B0EE-49FE-8E89-05FCAE91E1D4Q38323462-B237D97A-9DED-4FC2-AD12-A5B406526187Q38821469-80D1FDCC-F744-41C9-819D-FDA03E653C62Q38835717-F011F15E-A940-4FA3-9225-D8D4D97C8AC6Q38923923-11211F88-B0AC-41BD-B55A-53025FDFDF39Q39007021-64EC3253-4E83-48AD-97FD-25961A20E01BQ39044050-62EB1358-6028-49C0-8FDC-00F49C09CDF8Q39067701-A925FF09-28E3-43DC-9302-4435351F507CQ39093702-0DB0A7C7-6EA7-413F-8A95-6190C5CBEDA7Q39173469-C0E0D6DD-20B4-487C-8447-609B82F3DC96Q39225530-869F6413-64C3-4084-A721-2FFC78752BD7Q39269502-C51659BD-15C4-43DD-9DFC-C0CF4993654EQ39269509-D7D93147-730E-4445-9CC1-BC68EA6FBE79Q39526480-4601396E-CB41-47B0-9E90-A9D36320967EQ39552984-9C81D2A3-2DD6-42E7-A337-59F108DF754AQ39646708-295CC1E5-10AC-45C2-BB6B-5939A428CE5DQ39871943-A681E462-BC0F-4050-A8B4-CA2B42D019B3Q39946162-82EB28D5-13B5-459C-BD5F-56F8848C83CCQ39986052-50831068-1EC9-46B4-AE8B-2201488B8430Q40013376-4CCC8976-38CA-452E-B012-70C01C6B8257Q40061085-B1B818B4-40AB-49E2-B1C5-00A79FF8AB91Q40153959-D46F7831-C90F-429D-9484-3471A32E9C54Q40156780-96838B69-BFA6-4D26-A73D-7466DF9A7F41Q40367081-9CC6A126-8459-4EDF-81E4-D6843C3C931EQ40413314-F90189B1-1CC0-4730-94CA-3EF66B80DC39Q41493998-E6AA48F8-4AD1-43C2-9C5D-621B261CBB1BQ41595443-D8B12779-493C-4A98-B904-FC046C922F4FQ41917129-BFA3005B-E447-41C9-B24C-8B3CE075E48EQ41987483-5EBD7122-B4AA-4081-96FF-5A9843BB1B8BQ42252888-4CAF988C-17C1-405C-8028-80408BE89952Q42652831-45B1978F-62DD-4F85-8011-A74772B43C41Q42806314-9C1A8F78-4D6B-4905-B21F-08F381EA4B82Q42823322-86958DF8-8D2A-4A2E-8B82-D1BEBBD789FCQ43005376-05057805-902F-409C-8323-25ED1BDCF877Q43526791-8A4553CC-8CCD-46D7-86B9-15E45709196F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yuki Takahashi
@ast
Yuki Takahashi
@en
Yuki Takahashi
@es
Yuki Takahashi
@nl
Yuki Takahashi
@sl
type
label
Yuki Takahashi
@ast
Yuki Takahashi
@en
Yuki Takahashi
@es
Yuki Takahashi
@nl
Yuki Takahashi
@sl
prefLabel
Yuki Takahashi
@ast
Yuki Takahashi
@en
Yuki Takahashi
@es
Yuki Takahashi
@nl
Yuki Takahashi
@sl
P106
P1153
55555588900
P31
P496
0000-0002-8772-2772